Jane Street Group LLC Sells 13,210 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jane Street Group LLC trimmed its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 84.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,396 shares of the medical instruments supplier's stock after selling 13,210 shares during the period. Jane Street Group LLC's holdings in LeMaitre Vascular were worth $221,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. New York State Teachers Retirement System grew its position in LeMaitre Vascular by 1.2% in the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after purchasing an additional 100 shares in the last quarter. Flputnam Investment Management Co. grew its position in LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC grew its position in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares in the last quarter. Blue Barn Wealth LLC grew its position in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after acquiring an additional 104 shares during the period. Finally, Shaker Investments LLC OH grew its position in shares of LeMaitre Vascular by 0.8% in the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after acquiring an additional 112 shares during the period. Institutional investors own 84.64% of the company's stock.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 18,733 shares of LeMaitre Vascular stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the completion of the sale, the chief executive officer now owns 1,873,651 shares in the company, valued at $158,829,395.27. The trade was a 0.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 102,009 shares of company stock worth $8,721,836 in the last quarter. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Down 1.0%

Shares of NASDAQ LMAT traded down $0.81 during mid-day trading on Monday, reaching $83.32. 97,071 shares of the company were exchanged, compared to its average volume of 168,453. The company's 50-day simple moving average is $83.65 and its 200-day simple moving average is $90.74. The stock has a market capitalization of $1.88 billion, a P/E ratio of 45.53, a P/E/G ratio of 2.22 and a beta of 0.83. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.44 EPS. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is 40.40%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LMAT shares. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $97.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.